公开(公告)号：US20240361334A1

公开(公告)日：2024-10-31

申请号：US18290265

申请日：2022-05-11

Applicant: CISBIO BIOASSAYS

Inventor： Najim DOUAYRY ,  Patrick MENSAT ,  Thomas ROUX ,  Julie VALLAGHE ,  Eric TRINQUET

IPC: G01N33/68 ,  G01N33/542

CPC classification number: G01N33/6857 ,  G01N33/542 ,  G01N2333/4716

Abstract: The invention relates to a novel method for determining the binding of an antibody to the complement component 1q (C1q). The process according to the invention makes it possible to measure the binding of an antibody to the C1q in a Homogeneous Proximity Assay (HAS).

公开(公告)号：US20240255503A1

公开(公告)日：2024-08-01

申请号：US18565377

申请日：2022-05-25

Applicant: UNIVERSITY OF NEWCASTLE UPON TYNE

Inventor： Thomas HALLAM ,  Kevin MARCHBANK ,  David KAVANAGH ,  Claire HARRIS

IPC: G01N33/564 ,  C07K14/47 ,  G01N33/543

CPC classification number: G01N33/564 ,  C07K14/472 ,  G01N33/54373 ,  G01N2333/4716

Abstract: Aspects of the present invention relate to the detection of binding events associated with a protein complex comprised of a protease deficient Complement Factor I (FI) protein. Certain embodiments of the present invention provide for a protein complex comprising a Complement Factor I, C3b and further comprising at least one other protein from Complement Factor H (FH), Factor-H-like protein 1 (FHL-1), soluble membrane cofactor protein (sMCP), and soluble complement receptor 1 (sCR1), wherein the Complement Factor I comprises at least one mutation that causes inactivation of Complement Factor I protease activity. Further embodiments of the present invention provide for a protein complex comprising a Complement Factor I, C4b and further comprising at least one other protein from soluble complement receptor 1 (sCR1), soluble membrane cofactor protein (sMCP) and C4b binding protein (C4bp), wherein the Complement Factor I comprises at least one mutation that causes inactivation of Complement Factor I protease activity.

公开(公告)号：US12007391B2

公开(公告)日：2024-06-11

申请号：US17101693

申请日：2020-11-23

Applicant: TURUN YLIOPISTO

Inventor： Robert Moulder ,  Santosh Bhosale ,  David Goodlett ,  Harri Lähdesmäki ,  Olli Simell ,  Riitta Lahesmaa

IPC: G01N31/00 ,  G01N33/53 ,  G01N33/564 ,  G01N33/92

CPC classification number: G01N33/564 ,  G01N33/92 ,  G01N2333/47 ,  G01N2333/4713 ,  G01N2333/4716 ,  G01N2333/76 ,  G01N2333/775 ,  G01N2560/00 ,  G01N2570/00 ,  G01N2800/042 ,  G01N2800/50 ,  G01N2800/60

Abstract: The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.

公开(公告)号：US20230375544A1

公开(公告)日：2023-11-23

申请号：US18246792

申请日：2021-09-28

Applicant: Allegheny Singer Research Institute

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu

IPC: G01N33/564 ,  C07K16/18

CPC classification number: G01N33/564 ,  C07K16/18 ,  G01N2333/4716 ,  G01N2800/104 ,  C07K2317/31

Abstract: This disclosure provides a novel method for detecting one or more cell fragment-bound complement activation products (CFB-CAPs) using a capillary flow system. The method eliminates the need for fresh, live cellular samples and detection by flow cytometric methods. The method as disclosed has a wide variety of applications, including diagnosing or monitoring lupus or pre-lupus and other diseases or disorders (e.g., autoimmune or inflammatory diseases or disorders).

公开(公告)号：US20230212272A1

公开(公告)日：2023-07-06

申请号：US18000661

申请日：2021-06-04

Applicant: LONGBIO PHARMA (SUZHOU) CO., LTD.

Inventor： Nai-Chau SUN ,  Chow-Rou-Yun SUN ,  Qi GAO ,  Haili MA ,  Heng LIU

IPC: C07K16/18 ,  A61K47/68 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K47/6843 ,  G01N33/6893 ,  C07K2317/92 ,  C07K2317/24 ,  G01N2333/4716 ,  G01N2800/347

Abstract: An isolated antigen binding protein, which includes at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region and a method to encode an isolated nucleic acid molecule. A vector with the nucleic acid molecule. A cell with the nucleic acid molecule. A pharmaceutical composition with the isolated antigen binding protein. A method for preventing, alleviating or treating a CS-related disease or disorder. A method for detecting C5 in a sample.

公开(公告)号：US20190248839A1

公开(公告)日：2019-08-15

申请号：US16386179

申请日：2019-04-16

Applicant: Apellis Pharmaceuticals, Inc.

Inventor： Cedric Francois ,  Pascal Deschatelets ,  Monica Gerber

IPC: C07K7/64 ,  A61K47/64 ,  C07K14/475 ,  G01N33/564 ,  C07K14/005 ,  C12N7/00 ,  C07K14/47 ,  C07K7/08

CPC classification number: C07K7/64 ,  A61K38/00 ,  A61K47/645 ,  C07K7/08 ,  C07K14/005 ,  C07K14/472 ,  C07K14/475 ,  C07K2319/01 ,  C07K2319/10 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16033 ,  G01N33/564 ,  G01N2333/4716

Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.

公开(公告)号：US20190195861A1

公开(公告)日：2019-06-27

申请号：US16237382

申请日：2018-12-31

Applicant: ACEA Biosciences, Inc.

Inventor： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC: G01N33/50 ,  G01N27/02 ,  G01N33/543 ,  C12Q1/00

CPC classification number: G01N33/5041 ,  C12Q1/002 ,  G01N27/021 ,  G01N33/5014 ,  G01N33/5438 ,  G01N2333/4716 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method of identifying a therapeutic compound for treating cancer in a human subject, the method including: providing a device that measures cell-substrate impedance; culturing cancer cells in the at least two wells, wherein the cancer cells are obtained from a human subject and have a receptor tyrosine kinase (RTK) pathway; adding to a first well a proposed therapeutic compound that affects an RTK pathway and an RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells; and determining a difference in impedance or optionally in cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells of the human subject.

公开(公告)号：US20190187157A1

公开(公告)日：2019-06-20

申请号：US16281648

申请日：2019-02-21

Applicant: FUNDAÇÃO OSWALDO CRUZ

Inventor： Roney Santos COIMBRA ,  Rosiane A da Silva PEREIRA ,  Guilherme Correa DE OLIVEIRA ,  Ana Paula CORDEIRO

IPC: G01N33/68 ,  G01N33/569 ,  G01N33/53 ,  G01N33/92

CPC classification number: G01N33/6896 ,  G01N33/5308 ,  G01N33/56911 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/4716 ,  G01N2333/4737 ,  G01N2333/745 ,  G01N2333/775 ,  G01N2800/28 ,  G01N2800/50

Abstract: The instant invention relates to a qualitative predictive method, to a method, use and kit applied to the early differential diagnosis of the most prevalent forms of bacterial and viral meningitis, enabling to detect and distinguish the different forms of meningitis. The invention uses a qualitative predictive method based on combined detection and sequential analysis of the presence/absence of at least three out of four specific biomarkers.

公开(公告)号：US20180171337A1

公开(公告)日：2018-06-21

申请号：US15738564

申请日：2016-06-29

Applicant: Caris Science, Inc.

Inventor： Heather O'Neill ,  Mark Miglarese ,  David Spetzler

IPC: C12N15/115 ,  G01N33/53 ,  A61K47/68 ,  A61K31/711

CPC classification number: C12N15/115 ,  A61K31/711 ,  A61K47/6807 ,  C12N2310/16 ,  C12N2310/3513 ,  C12N2320/10 ,  G01N33/53 ,  G01N2333/4716 ,  G01N2333/70503 ,  Y02A50/411

Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.

公开(公告)号：US20170160276A1

公开(公告)日：2017-06-08

申请号：US15319515

申请日：2015-06-18

Applicant: TURUN YLIOPISTO

Inventor： Robert MOULDER ,  Santosh BHOSALE ,  David GOODLETT ,  Harri LÄHDESMÄKI ,  Olli SIMELL ,  Riitta LAHESMAA

IPC: G01N33/564 ,  G01N33/92

CPC classification number: G01N33/564 ,  G01N33/92 ,  G01N2333/47 ,  G01N2333/4713 ,  G01N2333/4716 ,  G01N2333/76 ,  G01N2333/775 ,  G01N2560/00 ,  G01N2570/00 ,  G01N2800/042 ,  G01N2800/50 ,  G01N2800/60

Abstract: The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.